BFM
UTHR icon

Boothbay Fund Management’s United Therapeutics UTHR Stock Holding History

Boothbay Fund Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,000
Closed -$1.26M – 2393
2025
Q3 		$1.26M Buy
+3,000
New +$1.01M 0.02% 742
2024
Q4 		– Sell
-810
Closed -$290K – 1926
2024
Q3 		$290K Buy
+810
New +$274K 0.01% 1269
2022
Q3 		– Sell
-5,104
Closed -$1.2M – 2612
2022
Q2 		$1.2M Buy
+5,104
New +$1.04M 0.03% 738
2021
Q4 		– Sell
-6,549
Closed -$1.21M – 2244
2021
Q3 		$1.21M Sell
6,549
-1,240
-16% -$244K 0.03% 670
2021
Q2 		$1.4M Sell
7,789
-1,658
-18% -$316K 0.04% 548
2021
Q1 		$1.58M Buy
9,447
+7,638
+422% +$1.27M 0.06% 407
2020
Q4 		$275K Buy
+1,809
New +$237K 0.01% 986
2017
Q2 		– Sell
-2,080
Closed -$282K – 848
2017
Q1 		$282K Buy
+2,080
New +$315K 0.05% 454

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Boothbay Fund Management's UTHR Position: Q4 2025 in Review

Boothbay Fund Management sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 3,000 shares — an estimated $1.26M sold.

Boothbay Fund Management first reported a position in UTHR in Q1 2017 and held it in 8 quarters. The position peaked at $1.58M in Q1 2021. 837 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Boothbay Fund Management reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 3,000 United Therapeutics shares in Q4 2025, an estimated $1.26M.
  • Boothbay Fund Management first reported a position in United Therapeutics in Q1 2017 and held it in 8 quarters.
  • Boothbay Fund Management's United Therapeutics position peaked at $1.58M in Q1 2021.
  • 837 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.